Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Almonertinib and Adebrelimab-based Chemo-immunotherapy in EGFR-mutant NSCLC
NCT06300424Phase 2Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Major Pathological Response. Started Apr 2024; status: active, not recruiting.
02
Drugs
almonertinibadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06300424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300424.